LQDA vs. NARI, PRCT, NVST, IRTC, NVCR, LIVN, ENOV, WRBY, TNDM, and LMAT
Should you be buying Liquidia stock or one of its competitors? The main competitors of Liquidia include Inari Medical (NARI), PROCEPT BioRobotics (PRCT), Envista (NVST), iRhythm Technologies (IRTC), NovoCure (NVCR), LivaNova (LIVN), Enovis (ENOV), Warby Parker (WRBY), Tandem Diabetes Care (TNDM), and LeMaitre Vascular (LMAT). These companies are all part of the "medical equipment" industry.
Liquidia vs.
Inari Medical (NASDAQ:NARI) and Liquidia (NASDAQ:LQDA) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.
91.0% of Inari Medical shares are owned by institutional investors. Comparatively, 64.5% of Liquidia shares are owned by institutional investors. 10.6% of Inari Medical shares are owned by insiders. Comparatively, 30.1% of Liquidia shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Inari Medical has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. Comparatively, Liquidia has a beta of 0.23, meaning that its stock price is 77% less volatile than the S&P 500.
In the previous week, Inari Medical had 2 more articles in the media than Liquidia. MarketBeat recorded 8 mentions for Inari Medical and 6 mentions for Liquidia. Inari Medical's average media sentiment score of 0.48 beat Liquidia's score of 0.34 indicating that Inari Medical is being referred to more favorably in the media.
Inari Medical currently has a consensus target price of $68.00, indicating a potential downside of 14.65%. Liquidia has a consensus target price of $25.38, indicating a potential upside of 78.32%. Given Liquidia's stronger consensus rating and higher possible upside, analysts plainly believe Liquidia is more favorable than Inari Medical.
Inari Medical has higher revenue and earnings than Liquidia. Inari Medical is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.
Inari Medical has a net margin of -13.68% compared to Liquidia's net margin of -765.38%. Inari Medical's return on equity of -10.09% beat Liquidia's return on equity.
Liquidia received 136 more outperform votes than Inari Medical when rated by MarketBeat users. Likewise, 68.24% of users gave Liquidia an outperform vote while only 57.89% of users gave Inari Medical an outperform vote.
Summary
Inari Medical beats Liquidia on 10 of the 19 factors compared between the two stocks.
Get Liquidia News Delivered to You Automatically
Sign up to receive the latest news and ratings for LQDA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Liquidia Competitors List
Related Companies and Tools
This page (NASDAQ:LQDA) was last updated on 2/1/2025 by MarketBeat.com Staff
